MEI Pharma's book value per share for the quarter that ended in Dec. 2023 was $8.93.
During the past 12 months, MEI Pharma's average Book Value Per Share Growth Rate was 23.00% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -35.60% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -22.10% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -20.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of MEI Pharma was 19.90% per year. The lowest was -56.20% per year. And the median was -15.70% per year.
MEI Pharma's current price is $3.07. Its book value per share for the quarter that ended in Dec. 2023 was $8.93. Hence, today's PB Ratio of MEI Pharma is 0.34.
During the past 13 years, the highest P/B Ratio of MEI Pharma was 11.36. The lowest was 0.34. And the median was 2.39.
Good Sign:
MEI Pharma Inc stock PB Ratio (=0.34) is close to 10-year low of 0.34
MEI Pharma Book Value per Share Historical Data
The historical data trend for MEI Pharma's Book Value per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of MEI Pharma's Book Value per Share
For the Biotechnology subindustry, MEI Pharma's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MEI Pharma's PB Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, MEI Pharma's PB Ratio distribution charts can be found below:
* The bar in red indicates where MEI Pharma's PB Ratio falls into.
MEI Pharma Book Value per Share Calculation
MEI Pharma's Book Value Per Share for the fiscal year that ended in Jun. 2023 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.
MEI Pharma (NAS:MEIP) Book Value per Share Explanation
Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.
For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.
MEI Pharma Book Value per Share Related Terms
Thank you for viewing the detailed overview of MEI Pharma's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
MEIP has been successfully added to your 